ClinicalTrials.gg
RecruitingNCT07006272STABILOOPUpdated Jul 28, 2025

Cohort Study to Refine the Positioning of Closed-loop Therapy Versus Islet Transplantation in the Management of Patients With Unstable Type 1 Diabetes

An observational study in Type 1 Diabetes (T1D), sponsored by University Hospital, Grenoble. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University Hospital, Grenoble.

Started
2025
with 1 other
Observational
7 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 18th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, or all of them as a file.
02

Study summary

Prospective, multicenter, descriptive cohort (RIPH3 study under the Jardé Act), STABILOOP study aims to describe whether BF may be an appropriate therapeutic option for the cohort of patients who are theoretically candidates for Islet transplantation, by describing Closed-Loop failures at 12 months in patients referred to an expert center for management of unstable diabetes.

03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • islet transplantation
  • closed loop
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged of minimum 18 years with Type 1 unstable diabetes, eligible to both Islet Transplant of Closed Loop treatement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Type 1 diabetic patients describing:

  • Significant glycaemic variability defined by the presence of one of these 3 criteria: - Standard deviation > 50% of the glycaemic mean or a MAGE index > 60 mg/dL
  • Coefficient of glycaemic variation > 36%
  • LBGI index > 5 or HYPOSCORE > 800
  • This glycaemic variability must be persistent, i.e. persist for more than 12 months despite optimal diabetes management by a multi-professional team. Optimum management involves :
  • Monitoring by a team with expertise in insulin pump and glucose sensor technologies
  • Training patients in functional insulin therapy, intensive self-monitoring of blood glucose levels, and prevention and management of situations where there is a risk of hypoglycaemia
  • Use of pump and glucose sensor therapy, with interruption before hypoglycaemia
  • Reinforced multi-professional support and monitoring, possibly combined with support via telemedicine.
  • This glycaemic variability must be considered as severe, i.e. causing unpredictable clinical and metabolic events that impair quality of life, such as severe, disabling and frequent hypoglycaemia (at least 2 Severe Hypoglycaemia with assistance from a third party in the last 12 months or at least 1 Severe Hypoglycaemia with life-threatening consequences in the last 12 months (coma, convulsions or trauma)) or ketosis ketoacidosis.

Exclusion criteria

Exclusion Criteria:

  • Patients with type 1 diabetes who do not meet the criteria for islet transplantation
  • Patients already fitted with a closed loop
  • Kidney transplant patients
  • Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons)
  • Persons opposed to participation in research
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • Closed Loop

    Patients who choose te be treated by Closed-Loop in routine care

  • Islet Graft

    Patients who choose te be treated by Islet Graft in routine care

06

What researchers measure

Primary outcomes

  1. Describe Closed Loop (CL) failures at 12 months in patients referred to an expert center for management of unstable diabetes.

    Proportion of patients on CL who have had in the year following the introduction of CL therapy : at least 2 severe hypoglycaemias (HS) with assistance from a third party or 1 life-threatening HS (coma or convulsion)

    Time frame: 12 months

Secondary outcomes

  1. Assess quality of glycaemic control in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Quality of glycaemic control for CL \& IG patients : \- Data sensor (TIR-TBR-TAR \> Glycaemic Target 70-140 \& 70-180), reported as percentage of time.

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  2. Assess the variation of the glycaemia management index in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Variation of glycaemia management index for CL \& IG patients : \- Data sensor GMI (%)

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  3. Assess glucose variability in patients treated with Closed Loop (CL) or Islet Graft (IG)

    glucose variability for CL \& IG patients : \- MAGE index

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  4. Assess glycaemia variability in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Data sensor Glycaemia variability for CL \& IG patients: \- CV (%)

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  5. Assess the level of mean glucose in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Level of blood glucose for CL \& IG patients : * Data sensor average daily blood glucose

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  6. Assess hypoglycemia awareness in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Hypoglycemia awareness for CL \& IG patients : \- Clarke score every 3 months for 1 year then every 6 months for 3 years

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months for 1 year then every 6 months for 3 years

  7. Assess balance between hypoglycaemia and hyperglycaemia in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Balance between hypoglycaemia and hyperglycaemia for CL \& IG patients : \- GRI glycaemic risk index

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  8. Assess the evolution of insulin requirement in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Insulin requirement for CL \& IG patients : \- insulin doses (IU/kg/day)

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  9. Assess glycaemia stability in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Glycaemia stability for CL \& IG patients : \- HbA1c (%)

    Time frame: Quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years 1st IG, depending on the date of inclusion in the study.

  10. Assess renal function in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Quality of renal function for CL \& IG patients : \- Creatininaemia (µmol/L) to estimate the glomerular filtration rate (mL/min/1.73m²)

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  11. Assess occurence of sever diabetic related events in patients treated with Closed Loop (CL) or Islet Graft (IG)

    For CL \& IG patients : \- sever hypoglycaemia (with assistance from a third party) / ketosis or ketoacidosis

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  12. Assess the level of endogenous production of insulin in patients treated with Islet Graft (IG)

    Level of C-peptide for IG patients : \- Fasting and stimulated C-peptide (nmol/L)

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  13. Assess the quality of the Islet Graft (IG)

    Quality of islet graft in IG patients : \- Graft function assessed by IGLS 2.0 score

    Time frame: Before CL initiation or quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after CL initiation or 1st IG, depending on the date of inclusion in the study.

  14. Assess the antidiabetic management in patients treated with Islet Graft (IG)

    Antidiabetic drug used in IG patients : \- Presence of antidiabetic drugs other than insulin (metformin, SLGT-2 inhibitor, GLP-1 analogues, DPP4 inhibitor, hypoglycaemic sulphonamides, glinides).

    Time frame: Quarterly pre-transplant follow-up, then every 3 months during 2 to 4 follow-up years after 1st IG, depending on the date of inclusion in the study.

  15. Assessing quality of life related to diabetes disease in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Describing quality of life questionnaires : DQOL (Diabetes Quality of Life Measure), score (0-100), higher scores = better quality of life

    Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.

  16. Assessing global quality of life in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Describing quality of life questionnaires : EQ-5D-5L (auto assessed health status questionnaire), score (0-1), higher scores = better health status

    Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.

  17. Assessing diabetes burden (diabetes-related emotional distress) in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Describing the burden of diabetes/questionnaires : T1-DDS (type 1 diabetes distress scale), score (28-168), higher scores = worse outcome

    Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.

  18. Assessing diabetes burden (fear of hypoglycemia) in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Describing the burden of diabetes: HFS (hypoglycemia fear score), score (0-132), higher scores = worse outcome

    Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.

  19. Assessing diabetes burden (impact and severity of fatigue) in patients treated with Closed Loop (CL) or Islet Graft (IG)

    Describing the burden of diabetes/questionnaires : FSS (fatigue severity scale), score (9-63), higher scores = worse outcome

    Time frame: Before CL/1st IG, and at 6, 12 and 24 months after CL/1st IG.

  20. Assess overall patient satisfaction of patients treated with Closed Loop (CL) or Islet Graft (IG)

    Describe patients' overall experience of their treatment modality(ies): \- DTSQ (diabetes treatment satisfaction questionnaire), score (0-36), higher scores = better treatment satisfaction

    Time frame: Before CL/1st IG, then at 6, 12, 24 months post-CL or post 1st IG (or just before a change in treatment modality such as failure of CL or IG)

  21. Assess overall patient satisfaction of patients treated with Closed Loop (CL)

    Describe patients' overall experience of their treatment modality(ies): \- INSPIRE questionnaire (insulin dosing systems: perceptions, ideas, reflections, and expectations), score (0-80), higher scores = more positive attitudes or greater perceived benefit/support

    Time frame: Before CL/1st IG, then at 6, 12, 24 months post-CL or post 1st IG (or just before a change in treatment modality such as failure of CL or IG)

  22. Evaluate the clinical course of diabetes treated with Closed Loop (CL) Islet Graft (IG).

    Clinical evolution criteria to be reported (first occurence): HS with assistance of a third party, hypoglycaemic comas, convulsions, cardiovascular events (acute coronary syndrome (ACS), stroke, transient ischaemic attack (TIA), amputations, haemorrhage, thrombosis) cancers, ketosis, ketoacidosis, hospitalisations, infections. The data collected will be reported according to the CTCAE v6 classification (classification terminology criteria for adverse events).

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  23. Identify the factors associated with Closed Loop (CL) treatment failures (hypoglycaemia)

    Identification if the "initial number of HS with assistance from a third party" prior to BF therapy is associated with the failure of BF therapy

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  24. Identify the factors associated with Closed Loop (CL) treatment failures (diabetes-related emotional distress)

    Identification if the "initial level of depression/anxiety or distress related to type 1 diabetes (T1-DDS questionnaire)" is associated with the failure of BF therapy

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  25. Identify the factors associated with Closed Loop (CL) treatment failures (fear of hypoglycemia)

    Identification if the "initial level of fear of hypoglycaemia (HSF questionnaire)" is associated with the failure of BF therapy

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  26. Identify the factors associated with Closed Loop (CL) treatment failures (HbA1c)

    Identification if the "initial level of HbA1 (%)" si associated with the failure of BF therapy

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  27. Identify the factors associated with Closed Loop (CL) treatment failures (TBR)

    Identification if the "initial level of % time below 70mg/dL" is associated with the failure of BF therapy

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  28. Describe the frequency of occurrence of severe hypoglycaemia with third-party assistance

    Incidence rate of severe hypoglycaemia with assistance of a third party

    Time frame: Throughout the follow-up period (from 2 to 4 years depending on the date of inclusion in the cohort)

  29. Assess the medico-economic impact at 2 years of islet transplantation compared with Closed Loop (CL) therapy from the perspective of the French healthcare system.

    The cost differential and the incremental cost-utility ratio (ICUR) will be analysed and expressed as the additional cost per healthy life-year gained with islet transplantation compared with CL therapy.

    Time frame: At 2 years post-equipment or post-transplant

07

Study locations

6 of 7 sites recruiting
  • HCL - Edouard Herriot Hospital
    Lyon, Auvergne-Rhône-Alpes 69437, France
    Recruiting
  • Hospices Civils de Lyon - Lyon Sud
    Pierre-Bénite, Auvergne-Rhône-Alpes 69310, France
    Recruiting
  • Strasbourg Civil Hospital
    Strasbourg, Grand Est 67000, France
    Recruiting
  • Grenoble University Hospital
    La Tronche, ISERE 38700, France
    Recruiting
    • Myriam HADDOUCHE · ContactMHaddouche@chu-grenoble.fr · +33663218329
    • Haddouche · Contact
    • Sandrine LABLANCHE, MD, PhD · Principal investigator
    • Quentin Perrier, PharmD, phD · Sub investigator
  • Montpellier University Hospital - Lapeyronnie Hospital
    Montpellier, Occitanie 34295, France
    Recruiting
  • Toulouse University Hospital - Hôpital Rangueil
    Toulouse, Occitanie 31059, France
    Recruiting
    • Marie-Blanche ARHAINX, MD · Contactarhainx.mb@chu-toulouse.fr · +33561323361
    • Hélène HANAIRE, MD, PhD · Principal investigator
  • APH Paris - LARIBOISIERE Hospital
    Paris, Île-de-France Region 75010, France
    Not yet recruiting
    • Djamila BELLILI, MD · Contactdjamila.bellili@aphp.fr · +33149959015
    • Jean-Pierre RIVELINE, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2030, 66 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 66 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 5, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Jun 30, 2031
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07006272
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jun 4, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jul 28, 2025

Study contacts

Myriam HADDOUCHE
Contact
mhaddouche@chu-grenoble.fr
+33476765509
Sandrine LABLANCHE, MD, PhD
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion